NLRP3 and cancer: RRx-001, an anti-cancer agent in phase III clinical trials, is currently identified as a highly selective NLRP3 inhibitor that covalently binds to cysteine 409 of NLRP3 and, therefore, blocks the assembly of the inflammasome [205].